Michael A. Sherman
Michelle Thanks everyone morning thanks us. and good joining and for
creating. invest record organization really population resources programs we're In restructured with to patients maximize in the we've months largest with to the greatest I biggest am since what impact execution activities the pleased our short objective As six an time potential of and I available all the track of joined, have those new the reflect need. has assessment accomplished on with organization to that the the in completed on the I of
as to frankly the compassionately are following acquired durable support and access efficiently most way stopped with done patients the patient diagnosis, identified we change For the we've we've to to point potential continued brincidofovir. fundamentally that is meaningful patients. immediately and benefit the drug elusive at which activities and exciting treated AML We've to an
with those the the aligned FDA well. on work to NDA and For going a that aligned be underway. experiments meeting. what even brincidofovir bridging performed BARDA also so are to we've we'll The remaining studies underway and pre-NDA in include the is brincidofovir We've on studies, final well prior
not our that indications. aggressively While already the development so patients opportunities do fit SymBio in value smallpox in other recognize brincidofovir there pursuing strategy, may a we there for for we is be brincidofovir who of outside shareholders identified partner viral and
two six the nine This rich timeframe Phase sense catalysts. commitment driving urgency X with focused to disciplined and to value look with of assets months hand is So with to the next we we've in forward execution same demonstrated recently. patient
next midyear For AML trial X DSTAT align for expect FDA first with line on Phase plans will pivotal a we initiate year. to to our trial and we the meet in that
funding smallpox. Success of we the to the add meeting stockpile the brincidofovir $XXX non-dilutive the our NDA planned to with step the a For national sets important to meet up hundreds end plants to we're as for to be brincidofovir to procurement stockpile submission. translate can only in will but manufacturing countermeasure security of worth for of clear our of To the process national positioning discuss XXXX. company. is before millions a product FDA for dollars stage for not million of to an deliver that This
success. for certainly and planning preparing we're So
in a little prostate Garrett the cancer Before AML. seven prior I opportunity experience DSTAT program and few five ago a therapies the that I'm vu hand to this to there me observations was more following about years handful let perception when little it approval having of over with indication. remained a that of make déjà in
the However disease ultimately patients. new options since a value metastatic refractory prostate then the addressing new Physicians of leaving the relapse those and investors would case opportunity provided void approvals flurry that similar is to disease. limited. of therapies in presents are cancer. targeted a Perceptions for first a therapies and AML story among progress the by agents despite therapies that have and treat remains of patients prevent recognized and populations enormous of then some with for niche that benefit for
reminded recently with nothing complete spoke there's complete AML I about physician a a me that in However response.
responding While short less rates these of are have remain to still do these in some for than We XX%. older five therapies to survival patients lot responses patients. and typically are a patients year work
and that mechanisms While is mechanisms others highly is a more proteins excites the been implicated in we leukemic there's delay have And and higher the within will treatment targets rates AML of where still first that of stem intent believe of hematologic us patients. in that about best recovery mechanism apply tremendous leukemic multiple even What that such line pursuing blasts it as DSTAT curative. an responses these cells that and where which the mechanistically are are in is chance even a patient targeted require mechanisms cure in indication disease to multimodal. durable heterogeneity multimodal survival
As without the also endpoints. Garrett more survival. will describe are regulatory parameters overall most detail These important disease for and important time in patients, improves clinical DSTAT
With to planning Phase XB trial let get over materially on that it's potential Phase is of we into how DSTAT data doesn't responses more data course for evidence durable the add matter X and some that updates that of benefit No to much eager attractive complete that slice we're brincidofovir. turn results why which makes that call X enrolling. Delivering toxicity more discuss me Phase the final of to for the the and randomized to these the therapy Garrett persists.
